SCHEMBL24336038

SCHEMBL24336038

CCOc1cc(OC)cc(-c2cc3cnc(Cl)nc3cc2F)c1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ FGFR1 P11362 14/20 0.46
▸ KDM4E B2RXH2 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ FGFR2 P21802 5/20 0.39
▸ FGFR4 P22455 5/20 0.39
▸ FGFR3 P22607 5/20 0.39
▸ KDR P35968 4/20 0.39
▸ PTGS2 P35354 1/20 0.37
▸ SRC P12931 1/20 0.36
▸ CYP11B1 P15538 1/20 0.36
▸ CYP11B2 P19099 1/20 0.36
▸ FLT1 P17948 2/20 0.34
▸ FLT4 P35916 2/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16668439 0.93 FGFR1 (0.52) FGFR1KDM4EALDH1A1SMN1; SMN2FGFR2
SCHEMBL29386366 0.93 FGFR1 (0.52) FGFR1KDM4EALDH1A1SMN1; SMN2FGFR2
SCHEMBL24335187 0.87 KDM4E (0.56) FGFR1KDM4EALDH1A1SMN1; SMN2FGFR2
SCHEMBL29385006 0.79 FGFR1 (0.55) FGFR1KDM4EALDH1A1SMN1; SMN2FGFR2
SCHEMBL16667808 0.79 FGFR1 (0.55) FGFR1KDM4EALDH1A1SMN1; SMN2FGFR2
SCHEMBL21910365 0.79 FGFR1 (0.55) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL20331733 0.79 NPC1 (0.51) FGFR1KDM4EALDH1A1SMN1; SMN2CYP11B1
SCHEMBL18612966 0.79 CYP11B1 (0.49) FGFR1KDM4EALDH1A1SMN1; SMN2FGFR2
SCHEMBL15413235 0.78 KDM4E (0.65) FGFR1KDM4EALDH1A1SMN1; SMN2FGFR2
SCHEMBL29385053 0.78 KDM4E (0.65) FGFR1KDM4EALDH1A1SMN1; SMN2FGFR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3395814-B1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORP (US) 2022-04-06 — — EP disclosed
Send feedback